Edesa Biotech is trading at $2.72, up 6.25% on October 29, 2026; no confirmed company announcement or reliable report explains the rise. - The October 15 FDA clearance for a Phase 2 vitiligo study is earlier news, not a confirmed catalyst for this move. - An October 28 update reported the EB05 COVID-19 trial terminated, but available coverage does not link it to the gain. - Major U.S. indexes were lower, so broad market direction does not explain the upward move.